Handa Pharmaceuticals, Inc. reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was TWD 40.96 million compared to TWD 13.75 million a year ago. Revenue was TWD 40.96 million compared to TWD 13.75 million a year ago.

Net loss was TWD 86.38 million compared to TWD 116.61 million a year ago. Basic loss per share from continuing operations was TWD 0.71 compared to TWD 1.01 a year ago. Diluted loss per share from continuing operations was TWD 0.71 compared to TWD 1.01 a year ago.

Basic loss per share was TWD 0.71 compared to TWD 1.01 a year ago. Diluted loss per share was TWD 0.71 compared to TWD 1.01 a year ago.